RT info:eu-repo/semantics/article
T1 Production of elastin-like recombinamer-based nanoparticles for docetaxel encapsulation and use as smart drug-delivery systems using a supercritical anti-solvent process
A1 González Valdivieso, Juan
A1 Vallejo, Reinaldo
A1 Santos, Mercedes
A1 Rodríguez Rojo, Soraya
A1 Arias Vallejo, Francisco Javier
K1 Elastin-like recombinamers (ELRs)
K1 Supercritical anti-solvent (SAS)
K1 Docetaxel
K1 Drug delivery
K1 Cancer therapy
AB This study presents a new groundbreaking methodology for integrating innovative concepts to develop novel drug-delivery strategies. This methodology combines genetically engineered elastin-like recombinamers (ELRs) with supercritical fluid (SCF) techniques to encapsulate a poorly water-solubledrug in a one-step process. The chemotherapeutic agent docetaxel (DTX) is encapsulated with a blockcopolymer ELR containing the RGD peptide, a specific target sequence for cancer cells, using thesupercritical anti-solvent (SAS) technique in a high process yield of up to 70%. SEM studies showspherical microparticles of 10 mm after encapsulation. After dispersion under physiological conditions,microparticles disaggregate into stable monodisperse nanoparticles of 40 nm size and - 30 mVz-potential. This protects the drug, as confirmed by NMR analysis, thereby increasing the watersolubility of DTX up to fifty orders of magnitude. The delivery process is governed by the Fick diffusion mechanism and indicates that the presence of DTX on the particles surface is practically negligible. Cellular assays showed that, due to the presence of the cancer target sequence RGD, breast cancer cells were more affected than human endothelial cells, thus meaning that the strategy developed in this work opens the way to new controlled release systems more precise than non-selective chemotherapeutic drugs.
PB Elsevier B.V.
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/65543
UL https://uvadoc.uva.es/handle/10324/65543
LA eng
NO Journal of Industrial and Engineering Chemistry 93 (2021) 361-374
DS UVaDOC
RD 22-dic-2024